Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus PROGESTERONE VAGINAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus PROGESTERONE VAGINAL.
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE vs Progesterone (Vaginal)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norethindrone acetate (progestin) and ethinyl estradiol (estrogen) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering endometrial lining to reduce implantation. Ethinyl estradiol (in 7-day extended regimen) maintains hormone levels. Ferrous fumarate provides iron supplementation.
Progesterone binds to progesterone receptors in the reproductive tract, converting proliferative endometrium to secretory endometrium, and reduces gonadotropin secretion, inhibiting ovulation.
One tablet (containing norethindrone acetate 1 mg, ethinyl estradiol 20 mcg, and ferrous fumarate 75 mg) orally once daily for 28-day cycle (21 active pills, 7 placebo with ferrous fumarate).
For progesterone deficiency (e.g., assisted reproductive technology, luteal phase support): 90 mg intravaginally once daily. For secondary amenorrhea: 45 mg intravaginally every other day for up to 12 doses, then 90 mg if needed. For threatened abortion: 200-400 mg intravaginally once or twice daily.
None Documented
None Documented
Norethindrone: Terminal half-life approximately 8–11 hours. Ethinyl estradiol: Terminal half-life approximately 13–27 hours (mean 17 hours). Clinical context: Steady state reached after 5–7 days.
The terminal elimination half-life of progesterone administered vaginally is approximately 5.5 to 6 hours (range: 4.5–8.0 hours) in women with normal renal and hepatic function. This short half-life necessitates twice-daily dosing for sustained effects.
Norethindrone acetate: Urine (39% as metabolites, 1% unchanged); Feces (35% as metabolites). Ethinyl estradiol: Urine (40% as glucuronide conjugates, <1% unchanged); Feces (40% as metabolites). Ferrous fumarate: Iron absorbed and utilized; unabsorbed iron excreted in feces.
Primarily hepatic metabolism; about 50-60% of metabolites are excreted renally as glucuronide conjugates, with approximately 30-40% eliminated via feces. Less than 1% of unchanged progesterone is excreted in urine.
Category D/X
Category A/B
Progestin
Progestin